Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Share this content:
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
 
Sponsors and Collaborators
AVAX Technologies
 
Contact
United States, Illinois
Julio D Doligosa
847-872-4019
julio.doligosa@ctca-hope.com

United States, Oklahoma
Sharrese Bishop, RN,BSN,CCRC
918-286-5898
Sharrese.bishop@ctca-hope.com

United States, Pennsylvania
Marty Weinar, MS, RN, CAGS
215-537-7569
marty.weinar@ctca-hope.com
 
Principal Investigators
Henry E Schea
AVAX Technologies
 
ClinicalTrials.gov Identifier
NCT00660101

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs